Genmab Announces Financial Results for the First Quarter of 2024
The U.S. Food and Drug Administration (U.S. FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) aimed at treating adult patients with relapsed or…
Astellas and Poseida Therapeutics Collaborate to Advance Innovative Allogeneic Cell Therapies for Cancer Treatment
Astellas Pharma Inc. (TSE: 4503) and Poseida Therapeutics, Inc. (NASDAQ: PSTX) have announced a strategic collaboration between Astellas’ subsidiary Xyphos Biosciences, Inc. and Poseida. The agreement aims to develop innovative…
4 Ideas for Honoring Teachers During Teacher Appreciation Week, May 6-10
Teacher Appreciation Week arrives annually during the first full week of May, serving as a dedicated time to recognize and celebrate the unwavering commitment of educators worldwide. It presents an…
Amgen Announces Financial Performance for Q1 2024
Summary of Financial Highlights: In the first quarter of 2024, the company experienced significant growth across various metrics: Overall, the company demonstrated robust growth in revenues and product sales, despite…
Alnylam Pharmaceuticals Releases Q1 2024 Financial Results and Highlights Recent Achievements
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced its financial results for the first quarter ending March 31, 2024, along with notable recent business achievements. Yvonne…
Moderna Unveils Financial Performance for Q1 2024 and Business Developments
Moderna, Inc. (NASDAQ: MRNA) has released its financial results for the first quarter of 2024, along with key updates on its business operations. Stéphane Bancel, the Chief Executive Officer of…
Biogen’s Advancements in Corporate Responsibility Initiatives
Biogen Inc. (Nasdaq: BIIB) has released its 2023 Corporate Responsibility Report, illustrating the company’s strides in adhering to ethical business practices for the betterment of all stakeholders. Christopher A. Viehbacher,…
Novartis Strikes Deal to Purchase Mariana Oncology, Bolstering Radioligand Therapy Portfolio
Novartis to Acquire Mariana Oncology, Enhancing Radioligand Therapy Portfolio Novartis has announced its agreement to acquire Mariana Oncology, a biotechnology company headquartered in Watertown, Massachusetts, specializing in the development of…
Calquence Combo Shows Significant Progression-Free Survival Boost in 1st-Line Mantle Cell Lymphoma: ECHO Phase III Study
Encouraging findings emerge from an interim analysis of the ECHO Phase III trial, indicating that AstraZeneca’s Calquence (acalabrutinib), when paired with standard-of-care chemoimmunotherapy—bendamustine and rituximab—achieved a significant improvement in progression-free…
Novo Nordisk’s Q1 2024 Revenue Surges: Up by 22% in Danish Kroner, 24% at Constant Exchange Rates, Reaching DKK 65.3 Billion
Novo Nordisk’s Q1 2024 Performance Highlights Growth and Expansion Novo Nordisk, a global healthcare company focusing on diabetes and other serious chronic diseases, has reported robust financial results for the…
I Lost the Ability to Speak, Walk, or Sit: A Glimpse into a Rare Autoimmune Disease Targeting Muscles
In January 2016, Elisa Glass began feeling fatigued and unsteady. As her symptoms worsened to include severe body aches and weakness reminiscent of painful charley horses, she sought help from…
WuXi AppTec Surpasses First Quarter 2024 Goals Amid External Obstacles, Sustaining Operational Stability
WuXi AppTec, a leading global provider of R&D and manufacturing services for the pharmaceutical and life sciences industry, has released its financial results for the first quarter ending March 31,…